Biotechnology company ImClone Systems Inc. said on Monday that a $60-per-share takeover bid from partner Bristol-Myers Squibb Co. was too low, but it would hire financial advisers to help it study the unsolicited offer.
*For more on this story,
read the full Reuters article.
